Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.

2014 
Abstract Background In patients with solid tumours, daily everolimus dosing demonstrated dose proportionality and linear pharmacokinetics. A meta-analysis was conducted to characterise the relationship between everolimus C min and efficacy and safety and the effect of CYP3A4 and P-glycoprotein (PgP) substrate/inhibitor/inducer coadministration on everolimus trough concentration ( C min ). Methods Individual patient data from five phase 2/3 studies, in which steady state, predose pharmacokinetic samples were taken from patients with solid tumours administered everolimus 10mg/day, were pooled. Findings Efficacy and safety were evaluable for 945 and 938 patients, respectively. A 2-fold increase in everolimus C min increased the likelihood of tumour size reduction (odds ratio 1.40, 95% confidence interval (CI) 1.23–1.60), was associated with a trend for reduced risk of progression-free survival events (risk ratio [RR] 0.90, 95% CI 0.69–1.18) and increased the risk of grade ⩾3 pulmonary (RR 1.93, 95% CI 1.12–3.34), stomatitis (RR 1.49, 95% CI 1.05–2.10) and metabolic (RR 1.30, 95% CI 1.02–1.65) events. Coadministering everolimus with strong CYP3A4 and PgP inhibitors increased everolimus C min by 10% and 20%, respectively; coadministration with CYP3A4 inducers reduced C min by 7%. Interpretation A 2-fold increase in everolimus C min was associated with improved tumour size reduction and increased risk of high-grade pulmonary, metabolic and stomatitis events. Funding Novartis Pharmaceuticals Corporation.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    25
    References
    58
    Citations
    NaN
    KQI
    []